analyzed 62 cases of stage IIB/IV RET fusion-positive NSCLC, including 41 KIF5B-RET, 15 CCDC6-RET, and 6 other rare fusion-positive subtypes. This evidence concerns the gene CCDC6 and non-small cell lung carcinoma.